EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1‐Linked Amyotrophic Lateral Sclerosis

Christina Steffke, Karthik Baskar, Franziska Bachhuber, Maximilian Wiesenfarth, Johannes Dorst, Joachim Schuster, Florian Schöberl iD, Peter Reilich, Martin Regensburger iD, Alexander German, René Günther, Maximilian Vidovic und 25 weitere

Annals of Neurology · 2025-12 · 98 (6) · 1318-1334

DOI: 10.1002/ana.70025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 09.08.2025. Verfasst von Christina Steffke und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Ulm University, Ulm, Germany. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Proteomics, Superoxide Dismutase-1. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Deutsche Gesellschaft für Muskelkranke, Alamar Biosciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Tofersen is the first effective and approved therapy for superoxide dismutase 1 ( SOD1 )‐associated amyotrophic lateral sclerosis (ALS [SOD1‐ALS]). Following treatment with tofersen, neurofilament levels in patients' cerebrospinal fluid (CSF) and serum seem to respond earlier than clinical parameters. This evidence prompted us to hypothesize that this novel treatment could provide an opportunity to identify additional biomarkers responsive to therapy in SOD1‐ALS.

Methods

We investigated a panel of 120 neural, glial, and inflammatory markers in CSF and serum samples longitudinally collected from a total of 28 SOD1‐ALS patients at baseline, and after 3, 6 and 12 months of treatment with tofersen, followed by validation with conventional methodology.

Results

We identified a set of proteins, including neurofilament light chain, neurofilament heavy chain, amyloid‐beta 1–40 and amyloid‐beta 1–42, neuropeptide Y (NPY), and ubiquitin C‐terminal hydrolase L1 (UCHL1), whose CSF levels both differed between SOD1‐ALS and the control group, and were responsive to tofersen at 3 and 6 months after treatment initiation. Another group of markers, including the neuropentraxin (NPTX) family members NPTX1, NPTX2 and NPTXR, did not separate untreated SOD1‐ALS from controls, but was responsive to tofersen. At 12 months on tofersen the levels of neurofilament light chain, neurofilament heavy chain, NPTX1, NPTX2, and NPTXR remained reduced compared with baseline, and correlated with the clinical response to tofersen. Consistent with increasing CSF pleocytosis and intrathecal immunoglobulin production, inflammatory markers were significantly increased after 12 months of treatment.

Interpretation

Our results highlight a complex, time‐dependent differential response of CSF biomarkers to tofersen treatment, and may pave the way for developing a panel of responsive proteins to make biomarker endpoints more robust in clinical trials for SOD1‐ALS and beyond. ANN NEUROL 2025;98:1318–1334

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisProteomicsSuperoxide Dismutase-1HumansMaleFemaleMiddle AgedBiomarkersAgedAdultNeurofilament ProteinsLongitudinal Studies

Substanzen

Superoxide Dismutase-1BiomarkersSOD1 protein, humanNeurofilament Proteinsneurofilament protein L

Autor:innen und Institutionen

  • Department of Neurology, Ulm University, Ulm, Germany.
  • Institute of Anatomy and Cell Biology, Ulm, Germany.
  • International Graduate School, Ulm University, Ulm, Germany.
  • German Center for Neurodegenerative Diseases (DZNE) Ulm, Ulm, Germany.
  • Department of Neurology with Friedrich Baur Institute, LMU University Hospital, München, Germany.
  • Department of Molecular Neurology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.

ORCID-Profile: Florian Schöberl, Martin Regensburger, Tim Hagenacker, Julian Grosskreutz, Patrick Weydt, Paul Lingor, Andreas Hermann, Johannes Prudlo, Simon Witzel, Patrick Oeckl, David Brenner, Alberto Catanese

Förderung

  • Deutsche Forschungsgemeinschaft
  • Deutsche Gesellschaft für Muskelkranke
  • Alamar Biosciences
  • Else Kröner-Fresenius-Stiftung

Zitieren

APA

Steffke, C., Baskar, K., Bachhuber, F., Wiesenfarth, M., Dorst, J., Schuster, J., Schöberl, F., Reilich, P., Regensburger, M., German, A., Günther, R., Vidovic, M., Petri, S., Meyer, T., Hagenacker, T., Grosskreutz, J., Weyen, U., Weydt, P., Haarmeier, T., …, & Catanese, A. (2025). Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1‐Linked Amyotrophic Lateral Sclerosis. Annals of Neurology, 98(6), 1318-1334. https://doi.org/10.1002/ana.70025

Vancouver

Steffke C, Baskar K, Bachhuber F, Wiesenfarth M, Dorst J, Schuster J, et al. Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1‐Linked Amyotrophic Lateral Sclerosis. Annals of Neurology. 2025;98(6):1318-1334. doi:10.1002/ana.70025

BibTeX
@article{Steffke2025,
  author = {Steffke, Christina and Baskar, Karthik and Bachhuber, Franziska and Wiesenfarth, Maximilian and Dorst, Johannes and Schuster, Joachim and Schöberl, Florian and Reilich, Peter and Regensburger, Martin and German, Alexander and Günther, René and Vidovic, Maximilian and Petri, Susanne and Meyer, Thomas and Hagenacker, Tim and Grosskreutz, Julian and Weyen, Ute and Weydt, Patrick and Haarmeier, Thomas and Lingor, Paul and Wolf, Joachim and Hermann, Andreas and Prudlo, Johannes and Günther, Kornelia and Knehr, Antje and Elmas, Zeynep and Uzelac, Zeljko and Witzel, Simon and Ruf, Wolfgang Philipp and Freischmidt, Axel and Ho, Ritchie and Ludolph, Albert C and Weishaupt, Jochen H and Tumani, Hayrettin and Oeckl, Patrick and Brenner, David and Catanese, Alberto},
  title = {Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1‐Linked Amyotrophic Lateral Sclerosis},
  journal = {Annals of Neurology},
  year = {2025},
  volume = {98},
  number = {6},
  pages = {1318--1334},
  doi = {10.1002/ana.70025}
}
Kostenlos starten →